Pioneer v. Inari: When Post-Priority Data Can Undermine Patent Enablement
Evidence created after a patent’s priority date is not automatically irrelevant to enablement. In Pioneer Hi-Bred International, Inc. v. Inari Agriculture, Inc., decided October 2, 2026, the Federal Circuit affirmed a Patent Trial and Appeal Board ruling that broad biotechnology claims were not enabled—and it approved the Board’s use of post-priority experimental data to test whether the specification actually taught the claimed genus.
The decision is nonprecedential, but it is still useful for patent applicants and litigants because it addresses a recurring question after Amgen v. Sanofi: when can later experimental evidence be used to evaluate whether a patent enabled its full claim scope as of the filing date?
The answer in Pioneer is nuanced. A challenger cannot use later-developed technology that did not exist at the priority date to impose an impossible disclosure burden on the inventor. But later testing may be relevant when it examines variants that could have been made at the priority date and shows that the specification’s claimed structural guidance does not reliably predict the required function.
The patent claimed a vast genus of herbicide-degrading enzymes
Pioneer’s U.S. Patent No. 11,371,055 concerns enzymes with a “dual herbicide-degrading function.” The enzymes were claimed to degrade both phenoxy auxin herbicides and pyridyloxy auxin herbicides, potentially making crops resistant to two different herbicide classes.
Representative claim 1 defined the genus using both function and structure. The claim required the dual herbicide-degrading function, at least 85% sequence identity with a disclosed sequence, and an AAD-12 motif.
Inari challenged claims 1–33 in post-grant review. According to the Federal Circuit, the claimed genus encompassed approximately 2.4 × 10106 species. Pioneer did not dispute the enormous size of the genus. The specification, by contrast, provided only two example species.
Even when the specification’s Figure 2 guidance was applied to narrow the possibilities, the universe remained approximately 1.23 × 1066 species. The Board concluded that the disclosure did not provide reliable guideposts for identifying which members of that massive genus would actually exhibit the required dual herbicide-degrading function.
The Federal Circuit’s nonprecedential opinion affirmed.
Pioneer’s own later testing became important evidence
With its patent owner response, Pioneer submitted experimental data generated more than a decade after the patent’s priority date. Eight enzymes satisfying the claimed structural limitations were tested for the dual herbicide-degrading function.
Only two of the eight showed the claimed dual function, and even those showed weak triclopyr activity. That result undercut Pioneer’s argument that the structural limitations—particularly the 85% sequence-identity requirement—provided a reliable way to predict function across the genus.
Inari relied on that data to argue that the patent’s structural guidance did not reliably correlate with the required function. The Board agreed, and Pioneer argued on appeal that the Board should not have relied on post-priority evidence at all because enablement must be judged as of the priority date.
The Federal Circuit rejected that categorical argument.
Enablement is measured at the priority date, but later evidence can still be probative
The court reaffirmed the basic rule that enablement is assessed as of the patent’s priority date. But that does not mean evidence generated later must be excluded.
The court relied on its earlier Amgen precedent, which recognized that post-priority evidence can be relevant when it sheds light on how much experimentation would have been required to practice the claimed invention at the priority date.
That distinction is important. The legal question remains historical: what did the specification teach a person of ordinary skill at the relevant filing date? Later evidence may simply help answer that historical question.
For example, later testing may reveal that a structural characteristic touted by the patent does not reliably predict the claimed function, or that extensive screening would have been required across a broad genus. Used that way, post-priority evidence does not change the state of the art. It tests whether the original disclosure actually supplied sufficient guidance.
The court distinguished later evidence from later-developed technology
Pioneer relied on cases such as In re Hogan and In re Entresto, where courts rejected enablement arguments based on technology or embodiments that did not exist at the priority date.
The Federal Circuit explained why those cases were different. In Hogan, the challenger relied on a form of polymer that was developed only after the filing date. In Entresto, the asserted enablement problem depended on a later-developed valsartan-sacubitril complex that did not exist when the application was filed.
Using those later inventions to invalidate an earlier patent would impose an impossible burden: the inventor could not have been expected to teach technology that had not yet been developed.
In Pioneer, however, the tested enzyme variants could have been created at the priority date. The experiments occurred later, but the subject matter being tested was not later-developed technology. That made the evidence relevant to whether the original disclosure enabled the claimed genus.
The scale of the genus mattered
The court also emphasized the disparity between the amount claimed and the amount actually disclosed. The Supreme Court’s Amgen decision framed the principle simply: the more one claims, the more one must enable.
Here, the specification supplied two examples against a claimed genus measured at an astronomical scale. Pioneer argued that sequence identity and other structural guidance allowed a skilled artisan to identify working species without undue experimentation.
But Pioneer’s own data weakened that theory. Only two of eight tested variants exhibited the claimed dual function. Two variants differed by only six amino acids, none at positions the patent’s guidance identified as presumptively important, yet one worked and the other did not.
The Federal Circuit concluded that substantial evidence supported the Board’s finding that the patent did not provide reliable guideposts at the 85% sequence-identity level.
What this means for biotechnology claim drafting
Functional genus claims can be commercially powerful because they attempt to protect a broad class of variants rather than a small list of specifically disclosed molecules or sequences. But broad functional language increases the enablement burden.
For biotechnology patent applications, it is not enough to identify a structural family and assert that most members should perform the claimed function. The specification should provide a technically credible relationship between structure and function, representative examples across the claimed range, and practical guidance that allows skilled artisans to identify working embodiments without a research program of undue scope.
Tucker Law’s patent application practice focuses on matching claim breadth to the technical disclosure. That often means asking during drafting whether the specification supports the full set of variants that the claim language will encompass, not merely the inventor’s preferred embodiment.
Later experiments can help—or hurt—a patent owner
Pioneer also illustrates a litigation risk: data introduced to support validity can become evidence against validity.
A patent owner may submit later experiments to show that variants across a broad genus perform as predicted. But if the results are mixed, the challenger may argue that the data demonstrates unpredictability and confirms that the original specification lacked reliable guidance.
That does not mean later testing should be avoided. It means the strategic implications should be evaluated before the data is generated or submitted. Experimental design, selection of variants, controls, thresholds for function, and the relationship between the testing and the patent’s disclosed teaching all matter.
The decision does not make all post-priority evidence admissible for every purpose
Because the opinion is nonprecedential, it should not be overstated. Nor does it announce that every later-created dataset can be used to attack enablement.
The key distinction is whether the evidence illuminates what a skilled artisan could have done based on the priority-date disclosure, or instead relies on later-developed technology to expand what the inventor supposedly had to enable.
That distinction can be important in patent litigation and PTAB proceedings. Parties should identify exactly what the later evidence proves and whether the tested subject matter was available or reasonably creatable at the priority date.
Post-grant review can expose Section 112 vulnerabilities early
The case also shows the reach of post-grant review. Unlike inter partes review, which is generally focused on anticipation and obviousness based on patents and printed publications, post-grant review can address broader patentability grounds, including Section 112 issues, when statutory eligibility requirements for PGR are satisfied.
For recently issued patents, that can make enablement a central PTAB issue. Patent owners should therefore assess the support for broad genus claims before issuance and again when preparing for potential post-grant challenges.
Tucker Law advises clients on Patent Trial and Appeal Board matters as part of an integrated prosecution and enforcement strategy.
The practical takeaway from Pioneer v. Inari
Pioneer reinforces three practical points. First, enablement remains fixed at the priority date. Second, later-generated evidence may still be relevant when it tests whether the original disclosure actually enabled subject matter that could have existed at that date. Third, exceptionally broad functional genus claims require correspondingly strong technical guidance.
For applicants, the drafting question is whether the specification teaches a repeatable path through the claimed scope. For patent owners, the litigation question is whether later experiments support that teaching or expose unpredictability. For challengers, the evidentiary question is whether post-priority testing fairly illuminates the original disclosure without relying on later-developed technology.
Tucker Law works with inventors and businesses on patent prosecution, PTAB proceedings, and patent disputes involving enablement and other Section 112 issues. To discuss a biotechnology patent, claim-scope issue, or validity challenge, contact Tucker Law.
This article provides general legal information and is not legal advice. Enablement depends on the particular claim language, disclosure, technology, level of skill, and evidentiary record.
